Cancer Epigenetics Training Program

癌症表观遗传学培训计划

基本信息

项目摘要

Project Summary The aim of the proposal is to develop a dedicated Training Program in Epigenetics and Cancer with a translational component at the Sylvester Comprehensive Cancer Center (SCCC), University of Miami Miller School of Medicine. The objective of the training program is to offer postdoctoral fellows a sophisticated, scientific environment with multidisciplinary expertise encompassing epigenetics and cancer. The proposed program will provide trainees with the ideal platform for successful careers as scientists, physicians, scientific administrators, and entrepreneurs that will identify novel agents and devises to treat cancer. We have assembled a team of 18 SCCC members who will serve as mentors of this program, including 9 full Professors, 7 Associate Professors, and 2 Assistant Professors. All mentors are currently supported by R01 and/or R01 equivalent funding (e.g. Leukemia Lymphoma Society) for at least the next two years at the time of submission. The total funding of these mentors exceeds seven million dollars per year. Most of these mentors have trained outstanding postdoctoral fellows in the past ten years. In addition, these mentors are currently training 12 postdoctoral fellows that are eligible for these training grants. The research expertise of these mentors includes hematologic malignancies, carcinogenesis, epigenetics, cancer genomics, cancer biology, signal transduction, drug discovery, cancer control, and bioinformatics. The models used in their labs include primary cells and cell lines from tumors and animal models relevant to human cancers, such as hematopoietic malignancies, breast cancer, uveal melanoma, lung cancer, pancreatic cancer, prostate cancer, and brain cancer. A training program has been advanced for the postdoctoral fellows within the Cancer Epigenetics Program at SCCC, aiming to engage them in multidisciplinary interactions where they can get exposure to clinical cancer research and learn about unmet research needs that they can then bring to the bench. This training program includes biweekly cancer epigenetic colloquia for trainees, a weekly journal club, seminars from outside speakers, monthly epigenomics working group meetings, and internal workshops for grant writing and bioinformatics. These approaches will allow the trainees to keep up with the most up-to-date research activities and to apply advanced techniques/methods into their studies, thereby increasing their competitiveness. In addition, individual development plans will be implemented for each trainee to maximize their unique strengths and overcome their specific weaknesses. Our training program will maximize diversity and make every effort to recruit trainees from populations traditionally underrepresented in science and medicine. With our enthusiastic and dedicated mentors, carefully selected trainees, a multidisciplinary environment, and a strong commitment from our Institution, the proposed program will provide unique opportunities for our trainees to flourish in multi-dimensional thinking, problem solving and laboratory skills, as well as establish a workforce that will successfully produce the next generation researchers in Epigenetics and Cancer.
项目摘要 该提案的目的是开发一个专门的表观遗传学和癌症培训计划, 迈阿密·米勒大学西尔维斯特综合癌症中心(SCCC)翻译部分 医学院。该培训计划的目标是为博士后研究员提供成熟、科学的 拥有表观遗传学和癌症等多学科专业知识的环境。拟议的计划将 为学员提供作为科学家、医生、科学管理人员等成功职业生涯的理想平台 以及将发现治疗癌症的新制剂和新设计的企业家。我们已经组建了一支18人的团队 将担任本项目导师的SCCC成员,包括9名正教授,7名副教授, 和2名助理教授。所有导师目前由R01和/或R01等值资金支持(例如 白血病淋巴瘤协会)在提交时至少在接下来的两年内。这些项目的总资金 导师每年的收入超过700万美元。这些导师大多培养了杰出的博士后 在过去的十年里。此外,这些导师目前正在培训12名博士后研究员,他们是 有资格获得这些培训补助金。这些导师的研究专长包括血液系统恶性肿瘤, 致癌,表观遗传学,癌症基因组学,癌症生物学,信号转导,药物发现,癌症 控制和生物信息学。他们实验室中使用的模型包括原代细胞和肿瘤细胞系以及 与人类癌症相关的动物模型,如血液系统恶性肿瘤、乳腺癌、葡萄膜黑色素瘤、 肺癌、胰腺癌、前列腺癌和脑癌。已经为以下人员提出了培训计划 SCCC癌症表观遗传学项目中的博士后研究员,旨在让他们参与 多学科互动,在那里他们可以接触到临床癌症研究并了解未满足的 他们需要研究,然后才能拿到法官席上来。该培训计划包括两周一次的癌症表观遗传学 学员座谈会,每周杂志俱乐部,外部演讲者研讨会,每月表观基因组学工作 小组会议,以及赠款撰写和生物信息学内部研讨会。这些方法将允许 学员将跟上最新的研究活动并将先进的技术/方法应用于 他们的学习,从而增加了他们的竞争力。此外,个人发展计划将是 为每个学员实施,以最大限度地发挥其独特的优势,克服其特定的弱点。我们的 培训计划将最大限度地增加多样性,并尽一切努力从传统人群中招募学员 在科学和医学界的代表性不足。与我们热情和敬业的导师一起,精心挑选 学员,多学科环境,以及我们机构的坚定承诺,拟议的计划 将为我们的学员提供独特的机会,让他们在多维思维、解决问题和 实验室技能,以及建立一支成功培养下一代研究人员的队伍 《表观遗传学与癌症》。

项目成果

期刊论文数量(11)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome.
  • DOI:
    10.1038/s41467-021-21588-4
  • 发表时间:
    2021-02-26
  • 期刊:
  • 影响因子:
    16.6
  • 作者:
    Kennedy AL;Myers KC;Bowman J;Gibson CJ;Camarda ND;Furutani E;Muscato GM;Klein RH;Ballotti K;Liu S;Harris CE;Galvin A;Malsch M;Dale D;Gansner JM;Nakano TA;Bertuch A;Vlachos A;Lipton JM;Castillo P;Connelly J;Churpek J;Edwards JR;Hijiya N;Ho RH;Hofmann I;Huang JN;Keel S;Lamble A;Lau BW;Norkin M;Stieglitz E;Stock W;Walkovich K;Boettcher S;Brendel C;Fleming MD;Davies SM;Weller EA;Bahl C;Carter SL;Shimamura A;Lindsley RC
  • 通讯作者:
    Lindsley RC
Integrator enforces the fidelity of transcriptional termination at protein-coding genes.
集成剂在蛋白质编码基因上执行转录终止的保真度。
  • DOI:
    10.1126/sciadv.abe3393
  • 发表时间:
    2021-11-05
  • 期刊:
  • 影响因子:
    13.6
  • 作者:
    Dasilva LF;Blumenthal E;Beckedorff F;Cingaram PR;Gomes Dos Santos H;Edupuganti RR;Zhang A;Dokaneheifard S;Aoi Y;Yue J;Kirstein N;Tayari MM;Shilatifard A;Shiekhattar R
  • 通讯作者:
    Shiekhattar R
Pharmacological Disruption of the Notch1 Transcriptional Complex Inhibits Tumor Growth by Selectively Targeting Cancer Stem Cells.
  • DOI:
    10.1158/0008-5472.can-20-3611
  • 发表时间:
    2021-06-15
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Alvarez-Trotta A;Guerrant W;Astudillo L;Lahiry M;Diluvio G;Shersher E;Kaneku H;Robbins DJ;Orton D;Capobianco AJ
  • 通讯作者:
    Capobianco AJ
NACK and INTEGRATOR act coordinately to activate Notch-mediated transcription in tumorigenesis.
  • DOI:
    10.1186/s12964-021-00776-1
  • 发表时间:
    2021-09-22
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Shersher E;Lahiry M;Alvarez-Trotta A;Diluvio G;Robbins DJ;Shiekhattar R;Capobianco AJ
  • 通讯作者:
    Capobianco AJ
Human hematopoiesis: aging and leukemogenic risk.
  • DOI:
    10.1097/moh.0000000000000622
  • 发表时间:
    2021-01
  • 期刊:
  • 影响因子:
    3.2
  • 作者:
    Adelman ER;Figueroa ME
  • 通讯作者:
    Figueroa ME
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Maria Eugenia Figueroa其他文献

Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia
抑制 DNA 甲基转移酶可激活肿瘤坏死因子 α 诱导的急性髓系白血病单核细胞分化
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Anna Laurenzana;L. Petruccelli;Filippa Pettersson;Maria Eugenia Figueroa;Ari Melnick;Albert S. Baldwin;Francesco Paoletti;Jr Wilson H. Miller
  • 通讯作者:
    Jr Wilson H. Miller

Maria Eugenia Figueroa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Maria Eugenia Figueroa', 18)}}的其他基金

Cancer Epigenetics Training Program
癌症表观遗传学培训计划
  • 批准号:
    10226244
  • 财政年份:
    2018
  • 资助金额:
    $ 26.8万
  • 项目类别:
Cancer Epigenetics Training Program
癌症表观遗传学培训计划
  • 批准号:
    9977979
  • 财政年份:
    2018
  • 资助金额:
    $ 26.8万
  • 项目类别:
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes
骨髓增生异常综合征中氮胞苷反应的表观遗传生物标志物
  • 批准号:
    9268794
  • 财政年份:
    2015
  • 资助金额:
    $ 26.8万
  • 项目类别:
Epigenetic biomarkers of response to Azacytidine in Myelodysplastic Syndromes
骨髓增生异常综合征中氮胞苷反应的表观遗传生物标志物
  • 批准号:
    8979977
  • 财政年份:
    2015
  • 资助金额:
    $ 26.8万
  • 项目类别:

相似海外基金

Molecular Epidemiological and pathological studies on the association between lipoprotein(a) and malignant neoplasms
脂蛋白(a)与恶性肿瘤关系的分子流行病学及病理学研究
  • 批准号:
    17K08718
  • 财政年份:
    2017
  • 资助金额:
    $ 26.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrated analysis and detection of new therapeutic target aimed for improvement of prognosis in the patients with pancreatic malignant neoplasms
综合分析检测改善胰腺恶性肿瘤患者预后的新治疗靶点
  • 批准号:
    24501337
  • 财政年份:
    2012
  • 资助金额:
    $ 26.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6116914
  • 财政年份:
    1998
  • 资助金额:
    $ 26.8万
  • 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6219852
  • 财政年份:
    1998
  • 资助金额:
    $ 26.8万
  • 项目类别:
GENETIC PREDISPOSITION TO SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD
儿童期后第二次恶性肿瘤的遗传倾向
  • 批准号:
    6278109
  • 财政年份:
    1997
  • 资助金额:
    $ 26.8万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305338
  • 财政年份:
    1996
  • 资助金额:
    $ 26.8万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305324
  • 财政年份:
    1996
  • 资助金额:
    $ 26.8万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2451660
  • 财政年份:
    1996
  • 资助金额:
    $ 26.8万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2451659
  • 财政年份:
    1996
  • 资助金额:
    $ 26.8万
  • 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CANCER OF THE OVARY
卵巢癌后的第二个恶性肿瘤
  • 批准号:
    2305309
  • 财政年份:
    1995
  • 资助金额:
    $ 26.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了